APA (7th ed.) Citation

Aaron, M., White, L., D'Andrea, K., Narayan, V., Knollman, H. M., Bradbury, A. R., . . . Shah, P. D. (2023). Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE). Journal of clinical oncology, 41(16_suppl), TPS1126. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS1126

Chicago Style (17th ed.) Citation

Aaron, Megan, et al. "Harnessing Olaparib, Palbociclib, and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative Metastatic Breast Cancer (HOPE)." Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1126. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS1126.

MLA (9th ed.) Citation

Aaron, Megan, et al. "Harnessing Olaparib, Palbociclib, and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative Metastatic Breast Cancer (HOPE)." Journal of Clinical Oncology, vol. 41, no. 16_suppl, 2023, p. TPS1126, https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS1126.